Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist.

Addy, Carol; Jumes, Patricia; Rosko, Kimberly; Li, Susie; Li, Hankun; Maes, Andrea; Johnson-Levonas, Amy O; Chodakewitz, Jeffrey; Stoch, S Aubrey; Wagner, John A

Addy, Carol; Jumes, Patricia; Rosko, Kimberly; Li, Susie; Li, Hankun; Maes, Andrea; Johnson-Levonas, Amy O; Chodakewitz, Jeffrey; Stoch, S Aubrey; Wagner, John A.

Affiliation

Addy C; Merck Research Laboratories, Boston, MA 02115, USA. carol_addy@merck.com

J Clin Pharmacol ; 49(10): 1228-38, 2009 Oct.

Article in En | MEDLINE | ID: mdl-19783715

Subject(s)

Amides/adverse effects; Anti-Obesity Agents/pharmacokinetics; Drug Inverse Agonism; Phentermine/adverse effects; Phentermine/pharmacokinetics; Pyridines/adverse effects; Receptor, Cannabinoid, CB1/antagonists & inhibitors; Adolescent; Adult; Amides/administration & dosage; Anti-Obesity Agents/adverse effects; Blood Pressure/drug effects; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Heart Rate/drug effects; Humans; Male; Middle Aged; Phentermine/administration & dosage; Pyridines/administration & dosage

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phentermine / Pyridines / Anti-Obesity Agents / Receptor, Cannabinoid, CB1 / Drug Inverse Agonism / Amides Type of study: Clinical_trials Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: J Clin Pharmacol Year: 2009 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google